Transdermal Therapeutic Systems

Sponsored by: LTS Lohmann Therapy Systems

Focused on:

  • Alternative Drug Delivery
  • Transdermal Therapeutic Systems

Date: 26 November


Time: 8AM London /5PM JST

Transdermal Therapeutic Systems - Still an attractive technology?!

Alternative drug delivery methods form an important part of the current global pharmaceutical market and its differing patient profiles and needs. Increasingly drug manufacturers and patients are looking at innovative and diverse drug delivery methods to reach the needs of a wider demographic.

TTS (Transdermal Therapeutic Systems) are an important sphere of drug delivery, one which should be considered alongside more traditional methods of delivery such as oral or parenteral. TTS provide a wide range of benefits which includes easy self administration; minimal pain levels; constant infusion-type delivery; avoid hepatic first-pass effect; reduce side effects; and dose reduction, amongst others.

This webinar will discuss the characteristics and advantages of TTS in relation to the feasibility of its usage to better/alternatively administer pharmaceutical actives and the novel possibilities to assess these advantages. The webinar will explore the history of the market success of TTS and the reasons therefore.
The webinar will also give an outlook on what is coming next in transdermal drug delivery e.g. microneedle systems.

Case Study 1: Japan specific product requirements exemplary shown by Exelon TTS

Case Study 2: TTS project evaluations - opportunities by in silico simulation of in vivo plasma profiles

Case Study 3: Market interest in China – value added generics through transdermal delivery

Presented by

Dr. Marco Emgenbroich,

Corporate Senior Director Head of Pharmaceutical Development

Dr. Marco Emgenbroich studied chemistry at the Heinrich-Heine University of Düsseldorf in Germany. He then joined a graduate school program on molecular physiology for PhD candidates and in early 2003 received his doctorate degree in organic and macromolecular chemistry.

After a postdoctoral fellowship in the biomedical applications of polymer matrices, Marco began his industrial career in the biotech field, where he worked on delivery of peptides and protein drug for parenteral applications.

Early in 2011 he joined the R&D department of LTS Lohmann Therapy Systems in Germany, where he was responsible for the late stage development program and global launch of the Neupro patch.
Since 2015, Marco has been responsible for pharmaceutical development teams working on collaboration projects in the area of transdermal therapeutic systems and oral thin films.

Key Learning Objectives

  • Understand the potential of transdermal therapeutic systems (TTS) in the pharmaceutical industry
  • Learn about territory specific approaches for transdermal delivery solutions
  • Learn about the rational development approach by combination of in vitro and in silico methods


  • Formulation Scientist
  • Drug Delivery Scientists
  • R&D Scientist
  • Formulation Pharmacist
  • Heads of Research and Development
  • Head of Pharmaceutical Technology
  • Director of Formulation
  • Director Formulation Development
  • Head of Product Development
  • Heads of Innovation Technology